NEWBURY PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.12 SEK | -4.59% |
|
+0.97% | +1.63% |
| Apr. 10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
| Feb. 22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 38.4M 3.54M | Sales 2025 * | 72.4M 6.67M | Capitalization | 75.69M 6.97M |
|---|---|---|---|---|---|
| Net income 2024 * | -10M -922K | Net income 2025 * | 3M 276K | EV / Sales 2024 * | 2.67 x |
| Net Debt 2024 * | 27M 2.49M | Net Debt 2025 * | 39M 3.59M | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 5 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.59% | ||
| 1 week | +0.97% | ||
| Current month | -8.50% | ||
| 1 month | -8.77% | ||
| 3 months | -30.82% | ||
| 6 months | -13.09% | ||
| Current year | +1.63% |
1 week
3.06
3.27
1 month
2.753.98
Current year
2.756.24
1 year
2.506.24
3 years
2.5013.70
5 years
2.5013.70
10 years
2.5013.70
| Managers | Title | Age | Since |
|---|---|---|---|
Lars Minor
CEO | Chief Executive Officer | 53 | 20-12-31 |
Christoffer Tell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
| Director/Board Member | - | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 50 | 19-12-31 | |
| Director/Board Member | 50 | 19-12-31 | |
Johan Strömqvist
BRD | Director/Board Member | 48 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 3.12 | -4.59% | 16,096 |
| 24-05-10 | 3.27 | +6.86% | 11,623 |
| 24-05-08 | 3.06 | +0.33% | 630 |
| 24-05-07 | 3.05 | -1.29% | 2,719 |
Delayed Quote Nasdaq Stockholm, May 13, 2024 at 10:49 am EDT
More quotes
Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Companyâs existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.
Sector
Drug Retailers
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.63% | 6.98M | |
| -9.69% | 8.83B | |
| +35.23% | 1.33B | |
| -8.81% | 370M | |
| +1.36% | 272M | |
| +13.33% | 232M | |
| -7.34% | 87.2M | |
| +20.94% | 59.19M |
- Stock Market
- Equities
- NEWBRY Stock